During the 1990s, Ferring accelerated the opening of new subsidiaries in Eastern and Western Europe, South America, Asia, South Africa…

The founder’s youngest son, Frederik Paulsen, became Chairman of the Ferring Group. At the same time Ferring established Ferring B.V.…

Ferring launched PENTASA® (mesalazine) for the treatment of inflammatory bowel diseases. This product enabled the company to strengthen its position…

The MINIRIN® tablet was the first peptide-based pharmaceutical to be successfully formulated for administration in tablet form.

Dr. Frederik Paulsen was one of the initiators of the Kiel Ferring Foundation, which, since its formation has awarded 20,000…

Ferring began forming global subsidiaries in Europe, North America and Southeast Asia.

First registration and launch of GLYPRESSIN® (terlipressin), an analogue of vasopressin, which is used for the treatment of bleeding oesophageal…

Ferring established its first production site outside Scandinavia in Kiel, Germany.

Ferring launched MINIRIN®, an anti-diuretic hormone used initially to treat diabetes insipidus and later primary nocturnal enuresis, or bedwetting. MINIRIN…

An important breakthrough for Ferring came when Dr. Paulsen and his staff succeeded in producing synthetic peptide hormones (vasopressin and…